Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Carlsmed (CARL) Cash from Financing Activities (2024 - 2026)

Carlsmed posted quarterly Cash from Financing Activities of $436000.0 for Q1 2026, down 96.27% year-on-year from $11.7 million in Q1 2025, and up 1603.45% on a QoQ basis from -$29000.0 in Q4 2025.

Carlsmed (CARL) has 3 years of Cash from Financing Activities data on file, last reported at $436000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Financing Activities fell 96.27% year-over-year to $436000.0; the trailing twelve-month figure through Mar 2026 stood at $88.9 million (changed N/A YoY), and the FY2025 full-year result was $100.1 million, up 71.16% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $436000.0, up from -$29000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $90.7 million in Q3 2025 and bottomed at -$2.2 million in Q2 2025.
  • The 3-year median for Cash from Financing Activities is $436000.0 (2026), against an average of $16.3 million.
  • The widest annual swing landed in 2025, when Cash from Financing Activities soared 551.41%; it then plunged 96.27% in 2026.
  • A 3-year view of Cash from Financing Activities shows it stood at -$51000.0 in 2024, then surged by 43.14% to -$29000.0 in 2025, then soared by 1603.45% to $436000.0 in 2026.
  • The last three Cash from Financing Activities figures came in at $436000.0 (Q1 2026), -$29000.0 (Q4 2025), and $90.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn -178.05 Mn
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn -70.02 Mn
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn -137.18 Mn
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn -112.85 Mn
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn -93.16 Mn
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn 13.46 Mn
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn -8.42 Mn
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn -10.67 Mn
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn 2.39 Mn
10 Carlsmed 298.68 Mn 201.48 Mn 12.43 Mn 436,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 436,000.00
Mar 31, 2026 436,000.00
Dec 31, 2025 -29,000.00
Dec 31, 2025 -29,000.00
Sep 30, 2025 90.70 Mn
Sep 30, 2025 90.70 Mn
Jun 30, 2025 -2.25 Mn
Jun 30, 2025 -2.25 Mn
Mar 31, 2025 11.70 Mn
Mar 31, 2025 11.70 Mn
Dec 31, 2024 -51,000.00
Dec 31, 2024 -51,000.00
Sep 30, 2024 13.92 Mn
Sep 30, 2024 13.92 Mn